Do analysts recommend ICU or BJDX?

SeaStar Medical presently has a consensus price target of $8.00, indicating a potential upside of 121.61%. Given SeaStar Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe SeaStar Medical is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer IRIX or BJDX?

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 237.08%. Given IRIDEX's stronger consensus rating and higher possible upside, research analysts clearly believe IRIDEX is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BJDX or CTSO?

Cytosorbents has a consensus target price of $107.50, suggesting a potential upside of 2,736.41%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts clearly believe Cytosorbents is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer TMDIF or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TMDIF or BJDX more profitable?

Titan Medical's return on equity of -82.31% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Bluejay Diagnostics N/A -125.00% -99.79%

Bluejay Diagnostics (BJDX) Competitors

$0.82 +0.01 (+1.02%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.80 -0.02 (-2.66%)

As of 10/9/2026 07:55 PM Eastern

Compare

BJDX vs. ICU, IRIX, CTSO, TMDIF, and NMTC

Should you buy Bluejay Diagnostics stock or one of its competitors? Bluejay Diagnostics's main competitors and comparable companies include SeaStar Medical (ICU), IRIDEX (IRIX), Cytosorbents (CTSO), Titan Medical (TMDIF), and NeuroOne Medical Technologies (NMTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bluejay Diagnostics compare to SeaStar Medical?

SeaStar Medical (NASDAQ:ICU) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

SeaStar Medical presently has a consensus price target of $8.00, indicating a potential upside of 121.61%. Given SeaStar Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe SeaStar Medical is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SeaStar Medical has a beta of -1.09, suggesting that its stock price is 209% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

In the previous week, SeaStar Medical had 6 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 7 mentions for SeaStar Medical and 1 mentions for Bluejay Diagnostics. SeaStar Medical's average media sentiment score of 0.28 beat Bluejay Diagnostics' score of 0.00 indicating that SeaStar Medical is being referred to more favorably in the media.

Company	Overall Sentiment
SeaStar Medical	Neutral
Bluejay Diagnostics	Neutral

1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bluejay Diagnostics has a net margin of 0.00% compared to SeaStar Medical's net margin of -795.51%. Bluejay Diagnostics' return on equity of -125.00% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	-795.51%	-162.75%	-109.89%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

Bluejay Diagnostics has lower revenue, but higher earnings than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	$1.71M	9.29	-$12.15M	-$3.91	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

Summary

Bluejay Diagnostics beats SeaStar Medical on 8 of the 15 factors compared between the two stocks.

How does Bluejay Diagnostics compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

20.1% of IRIDEX shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 8.6% of IRIDEX shares are held by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 237.08%. Given IRIDEX's stronger consensus rating and higher possible upside, research analysts clearly believe IRIDEX is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, IRIDEX had 132 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 133 mentions for IRIDEX and 1 mentions for Bluejay Diagnostics. IRIDEX's average media sentiment score of 0.82 beat Bluejay Diagnostics' score of 0.00 indicating that IRIDEX is being referred to more favorably in the media.

Company	Overall Sentiment
IRIDEX	Positive
Bluejay Diagnostics	Neutral

IRIDEX has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

IRIDEX has higher revenue and earnings than Bluejay Diagnostics. IRIDEX is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.30	-$4.44M	-$0.20	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

Bluejay Diagnostics has a net margin of 0.00% compared to IRIDEX's net margin of -6.88%. IRIDEX's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.88%	N/A	-12.55%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

Summary

IRIDEX beats Bluejay Diagnostics on 12 of the 15 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Cytosorbents?

Bluejay Diagnostics (NASDAQ:BJDX) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Cytosorbents has a consensus target price of $107.50, suggesting a potential upside of 2,736.41%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts clearly believe Cytosorbents is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bluejay Diagnostics has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. Bluejay Diagnostics' return on equity of -125.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-125.00%	-99.79%
Cytosorbents	-48.94%	-431.65%	-41.94%

In the previous week, Bluejay Diagnostics and Bluejay Diagnostics both had 1 articles in the media. Bluejay Diagnostics' average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Cytosorbents	Neutral

Bluejay Diagnostics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Bluejay Diagnostics has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A
Cytosorbents	$37.06M	0.32	-$8.20M	-$5.80	N/A

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 7.8% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cytosorbents beats Bluejay Diagnostics on 9 of the 13 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Titan Medical's return on equity of -82.31% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 0.0% of Titan Medical shares are held by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Bluejay Diagnostics had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for Bluejay Diagnostics and 0 mentions for Titan Medical. Titan Medical's average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.

Company	Overall Sentiment
Titan Medical	Neutral
Bluejay Diagnostics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Titan Medical has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.69	$6.95M	$0.05	2.13
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

Summary

Titan Medical beats Bluejay Diagnostics on 7 of the 11 factors compared between the two stocks.

How does Bluejay Diagnostics compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, NeuroOne Medical Technologies had 10 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 11 mentions for NeuroOne Medical Technologies and 1 mentions for Bluejay Diagnostics. NeuroOne Medical Technologies' average media sentiment score of 0.70 beat Bluejay Diagnostics' score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroOne Medical Technologies	Positive
Bluejay Diagnostics	Neutral

NeuroOne Medical Technologies has higher revenue and earnings than Bluejay Diagnostics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	0.84	-$3.61M	-$0.95	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

NeuroOne Medical Technologies has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bluejay Diagnostics has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -71.50%. Bluejay Diagnostics' return on equity of -125.00% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

NeuroOne Medical Technologies presently has a consensus target price of $7.33, suggesting a potential upside of 554.76%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NeuroOne Medical Technologies beats Bluejay Diagnostics on 10 of the 15 factors compared between the two stocks.

Get Bluejay Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BJDX vs. The Competition

Export

Metric	Bluejay Diagnostics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.64M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-0.12	25.57	274.15	26.16
Price / Sales	N/A	83.25	635.98	107.42
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	0.10	5.93	11.21	6.34
Net Income	-$6.85M	$146.18M	$3.50B	$381.90M
7 Day Performance	-1.52%	-0.38%	-0.90%	-1.41%
1 Month Performance	-18.43%	-2.02%	-4.44%	-3.48%
1 Year Performance	-93.54%	5.08%	6.96%	1.16%

Bluejay Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BJDX Bluejay Diagnostics	0.3676 of 5 stars	$0.82 +1.0%	N/A	-93.7%	$3.64M	N/A	N/A	6
ICU SeaStar Medical	3.0242 of 5 stars	$3.33 +4.4%	$8.00 +140.2%	-40.2%	$14.68M	$1.71M	N/A	2	Gap Up High Trading Volume
IRIX IRIDEX	2.8317 of 5 stars	$0.76 +11.2%	$3.00 +296.8%	-20.5%	$13.30M	$51.57M	N/A	108	Gap Up High Trading Volume
CTSO Cytosorbents	2.0503 of 5 stars	$3.95 -0.3%	$107.50 +2,621.5%	-79.7%	$12.45M	$37.22M	N/A	129
TMDIF Titan Medical	N/A	$0.10 -5.7%	N/A	-77.3%	$11.40M	$17.63M	N/A	50	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BJDX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. ICU, IRIX, CTSO, TMDIF, and NMTC

How does Bluejay Diagnostics compare to SeaStar Medical?

Summary

How does Bluejay Diagnostics compare to IRIDEX?

Summary

How does Bluejay Diagnostics compare to Cytosorbents?

Summary

How does Bluejay Diagnostics compare to Titan Medical?

Summary

How does Bluejay Diagnostics compare to NeuroOne Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. ICU, IRIX, CTSO, TMDIF, and NMTC

How does Bluejay Diagnostics compare to SeaStar Medical?

Do analysts recommend ICU or BJDX?

Which has more risk and volatility, ICU or BJDX?

Does the media favor ICU or BJDX?

Do insiders & institutionals believe in ICU or BJDX?

Is ICU or BJDX more profitable?

Which has higher valuation & earnings, ICU or BJDX?

Summary

How does Bluejay Diagnostics compare to IRIDEX?

Do institutionals and insiders believe in IRIX or BJDX?

Do analysts prefer IRIX or BJDX?

Does the media prefer IRIX or BJDX?

Which has more volatility & risk, IRIX or BJDX?

Which has higher earnings and valuation, IRIX or BJDX?

Is IRIX or BJDX more profitable?

Summary

How does Bluejay Diagnostics compare to Cytosorbents?

Do analysts recommend BJDX or CTSO?

Is BJDX or CTSO more profitable?

Does the media refer more to BJDX or CTSO?

Which has more risk & volatility, BJDX or CTSO?

Which has higher valuation and earnings, BJDX or CTSO?

Do insiders and institutionals hold more shares of BJDX or CTSO?

Summary

How does Bluejay Diagnostics compare to Titan Medical?

Which has more risk and volatility, TMDIF or BJDX?

Is TMDIF or BJDX more profitable?

Do institutionals and insiders believe in TMDIF or BJDX?

Does the media prefer TMDIF or BJDX?

Do analysts prefer TMDIF or BJDX?

Which has preferable earnings and valuation, TMDIF or BJDX?

Summary

How does Bluejay Diagnostics compare to NeuroOne Medical Technologies?

Does the media refer more to NMTC or BJDX?

Which has stronger earnings and valuation, NMTC or BJDX?

Which has more risk and volatility, NMTC or BJDX?

Do institutionals and insiders have more ownership in NMTC or BJDX?

Is NMTC or BJDX more profitable?

Do analysts prefer NMTC or BJDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools